Skip to main content

Table 2 Characteristics of the study population 3 months prior treatment initiation, at baseline and during follow-up period (6 and 12 months after first endobronchial infusion of ADSCs-SVF)

From: A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis

Characteristics 3 months prior infusion Baseline data 6 months post-1stinfusion 12 months post 1stinfusion
Total number of patients 5 14 14 14
Male 4 12 NA NA
Body weight (kgr) 79.6±11.2 79.6±11.2 77.1±8.6 76.2±9.4
Age (yrs) NA 64.4±7 NA NA
Ex smokers 5 14 NA NA
Current smokers 0 0 NA NA
Previous treatment with corticosteroids 5 5 NA NA
Other treatment (NAC) 5 5 NA NA
HRCT 5 (typical UIP pattern) 14 (typical UIP pattern) NA NA
VATS 2 (typical UIP pattern) 6 (2 typical and 4 probable UIP pattern) NA NA
Emphysema (HRCT) 2 4 NA NA
sPAP (mmHg) (cardiac echo) 29.6 ±9 29.6 ±9 31.5±7 32.4±4
FVC%pred 71.8 ±11.5 71.2±15.2 73.4 ± 18.1 74.4 ± 17.5
DLCO%pred 45.82±9.5 48.4±11.1 48.9 ± 12.8 47.3 ± 12.9
6MWD 501±67.9 472.1±55.2 477.1 ± 50.3 476.4 ± 51.9
mMRC 2.0 ± 0.3 2.1 ± 0.6 1.7 ± 0.6 1.7 ± 0.4
SGRQ NA 35.1±6.8 27.8 ± 5.6* 28.4 ± 5.7*
  1. Values are expressed as mean ± SD unless otherwise indicated.
  2. Abbreviations: 6MWD 6-minute Walking Distance, ADSCs-SVF Adipose derived stromal cells-stromal vascular fraction, DL CO Diffusion lung capacity for carbon monoxide, FVC Forced Vital Capacity, HRCT High resolution computed tomography, IPF Idiopathic pulmonary fibrosis, mMRC Modified medical research council, NA Non applicable, NAC N-Acetylcysteine, SGRQ Saint George’s Research Questionnaire, sPAP Systolic pulmonary artery pressure, UIP Usual Interstitial Pneumonia, VATS Video-Assisted thoracoscopic surgery.
  3. *p<0.05 was considered as statistically significant.